Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week. BMS is ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Hosted on MSN
Master your LiFePO4 solar backup setup
LiFePO4 batteries are changing the way solar backup systems work by delivering consistent performance, safety, and durability. To get the most from them, careful setup is needed—matching them with the ...
The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results